A detailed history of Manhattan West Asset Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Manhattan West Asset Management, LLC holds 453 shares of VRTX stock, worth $214,178. This represents 0.06% of its overall portfolio holdings.

Number of Shares
453
Holding current value
$214,178
% of portfolio
0.06%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $177,942 - $219,945
453 New
453 $212,000
Q4 2023

Feb 12, 2024

BUY
$343.0 - $410.68 $193,795 - $232,034
565 New
565 $229,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Manhattan West Asset Management, LLC Portfolio

Follow Manhattan West Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manhattan West Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Manhattan West Asset Management, LLC with notifications on news.